Benmelstobart plus chemo for early-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs (Benmelstobart immunotherapy plus chemotherapy, with or without Anlotinib) before surgery for people with limited-stage small cell lung cancer. The goal is to see if these drugs help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small cell lung cancer (SCLC) that hasn't spread widely (Stage I to IIIB).
- You have not had any prior cancer treatment, except for possibly one cycle of chemotherapy.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your major organs (like bone marrow, liver, and kidneys) are working well enough, based on blood tests.
- You do not have active cancer in the brain, other cancers within the past 5 years, or certain serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) together with chest radiation to treat small cell lung cancer that hasn't spread widely and cannot be removed with surgery. The goal is to see if this combination helps people live longer and controls their cancer better.
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.